Physician profile
David Oliver
NPI 1114319803
$1,790.76
in general payments reported to CMS, 2019-2025
23 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $186 · 2023: $199 · 2024: $319 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956 · Education: $499 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.54 |
| Education | $499.28 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $383.89 | 2022-2025 | |
| Sobi, INC | $199.90 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $150.00 | 2024 | Talvey |
| Caris Mpi, INC. | $115.11 | 2025 | Mi Cancer Seek |
| Merck Sharp & Dohme LLC | $104.70 | 2025 | Keytruda, Keytruda Qlex, Welireg |
| Lilly USA, LLC | $101.43 | 2023 | |
| Tempus Ai, INC | $97.54 | 2024-2025 | Xt Cdx |
| Novocure INC. | $95.47 | 2025 | Optune Gio |
| E.R. Squibb & Sons, L.L.C. | $74.36 | 2025 | Opdivo |
| Janssen Biotech, INC. | $73.59 | 2025 | Rybrevant |
| Beone Medicines USA, INC. | $69.16 | 2025 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $52.88 | 2025 | |
| Taiho Oncology, INC. | $49.93 | 2025 | |
| Pfizer INC. | $38.92 | 2025 | |
| Glaxosmithkline, LLC. | $31.20 | 2025 | Jemperli, Zejula, Blenrep |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $26.72 | 2025 | Lynparza |
| Adaptive Biotechnologies Corporation | $22.41 | 2025 | Clonoseq |
| Kyowa Kirin, INC. | $20.40 | 2025 | |
| Springworks Therapeutics, INC. | $18.54 | 2025 | Gomekli |
| Tersera Therapeutics LLC | $17.76 | 2025 | Zoladex |
| Abbvie INC. | $16.72 | 2025 | |
| Pharmaessentia USA Corporation | $15.67 | 2025 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $14.46 | 2025 | Fruzaqla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.